Introduction
Previous prostate cancer GWAS have reported associations between various SNPs and prostate cancer in cohorts of prostate cancer cases unselected for family history (Amundadottir et al. 2006; Duggan et al. 2007; Gudmundsson et al. 2007a Gudmundsson et al. , b, 2008 Haiman et al. 2007; Eeles 2008; Salinas et al. 2008; Sun et al. 2008; Thomas et al. 2008) . The International Consortium for Prostate Cancer Genetics (ICPCG) selected 25 of these SNPs to pursue replication of these findings in a set of related hereditary prostate cancer cases selected for membership in high-risk pedigrees. A previous analysis of the ICPCG data used familybased association testing (FBAT) on 102-477 informative families and was able to confirm three of these candidate SNPs [p ≤ 2E −3 (=0.05/25)] (Jin et al. 2012 ). Here, a larger analysis of the same 25 SNPs in over 12,000 individuals was conducted using a case-control framework that allowed analysis of all data submitted by ICPCG member sites without restriction to the trio relationship structure. The increased sample size considerably improves statistical power to study these SNPs.
Fourteen study sites contributed a total of 12,506 samples for genotyping, including 2,946 controls, 6,192 cases with non-aggressive disease, and 3,368 cases with aggressive disease. Genotyped samples originated from 2,283 pedigrees. Each site contributed its own controls, with an average of 231 controls per site, except for 1 site that provided genotype data for 931 genetically matched publicly available controls. It is well-known that close relationships can have an inflationary effect on statistics for tests of association; therefore, it was necessary to account for known relationships in the analysis. Genie software was used to accomplish this (Allen-Brady et al. 2005; Curtin et al. 2007) . Genie generates an empirical null distribution, matched for the known pedigree structures and multiple sites, from which to assess the observed test statistic for significance. In this study, 10 million such simulations were used to estimate the necessary null distributions. Separate analyses for all familial prostate cancers and the subset of aggressive prostate cancers were conducted.
Methods and materials

Sample cohort
Fourteen member sites of the ICPCG consortium provided samples for analysis; these sites were the African American Hereditary Prostate Cancer Consortium (AAHPC), the Anglo/Canadian/Texan/Australian/Norwegian/European Union Biomed (ACTANE), University of Tampere (Finland), Fred Hutchinson Cancer Research Center (FHCRC), Centre de Recherche pour les Pathologies Prostatiques (France), Johns Hopkins University (JHU), the Mayo Clinic (Mayo), The University of Michigan (Michigan), The University of Montreal (Montreal), Northwestern University (NW), Stanford University (Stanford), University of Umeå (Sweden), University of Ulm (Ulm), and University of Utah (Utah). Each site recruited study participants according to their own protocols; however, for consistency, confirmation from either death certificate or medical records was required for a diagnosis of prostate cancer. Table 1 provides the number of cases analyzed from each site. Each site also provided control samples, which were unaffected pedigree members, regionally selected and ethnically matched controls, or (for one site) in silico controls. The in silico controls were supplied by Michigan, who provided 931 controls from the Illumina Genotype Control Database (iControlDB) (http://www.illumina. com) that had been genetically matched to their set of cases using 610K SNPs [genomic inflation factor (Clayton et al. 2005 ) of 1.018]. Several sites also provided population ascertained cases (non-familial) that were used as another comparator group in a secondary genetic risk score analysis (n = 1,872).
All cases analyzed in this study from all study sites were of Caucasian ethnic background with the exception of the cases supplied by the AAHPC site which were all from African American pedigrees.
Phenotypes
In order to address the potential for clinical heterogeneity across all sites, we imposed standardized criteria for prostate cancer status. All prostate cancer cases were confirmed by death or medical record. Each was designated as nonaggressive, aggressive, or undetermined aggressive status. Cases were considered aggressive if they were categorized 1 3 as regional or distant stage, poorly differentiated or nondifferentiated grade, or had evidence for death due to metastatic prostate cancer (Schaid et al. 2006; Christensen et al. 2007) . Two phenotypes were analyzed. The first phenotype consisted of all prostate cancer cases in the pedigrees regardless of aggressiveness. A separate analysis of aggressive cases only was also performed; with comparisons made both to controls and to all non-aggressive prostate cases.
Genotypes
SNPs were selected for genotyping based on previously published reports that an allele at the SNP was significantly associated with prostate cancer; SNPs are shown in Table 2 . These SNPs occurred at cytogenetic bands 2p15, 3p12, 6q25, 7p15, 7q21, 8q24, 9q33, 10q11, 10q26, 11q13, 17q12, 17q24, 19q13 and Xp11 . Genotyping was performed with MassARRAY iPLEX (Sequenom, Inc., San Diego, CA, USA) at the Center for Cancer Genomics, Wake Forest University and is further described elsewhere (Jin et al. 2012) . Since imputation of missing genotypes is not possible given the paucity of genotyped SNPs, individuals with missing data at particular SNPs were ignored in those analyses.
Statistical methods
The vast majority of the cases analyzed in this study reside in high-risk pedigrees. It is well-known that standard association techniques are not appropriate for related individuals due to lack of independence of genotypes. Analyses were conducted with Genie software, which allows for valid analysis of all data, whether independent or not. To account for relatedness, Genie software compares the observed test statistic to an empirical null distribution derived from simulated data sets matched for pedigree structure but generated under the null hypothesis. In brief, the pedigree founders are assigned alleles based on their population frequencies and alleles of subsequent pedigree members are assigned according to random Mendelian inheritance of the founder alleles (a 'gene-drop'). Test statistics are calculated for each null simulation to determine a null distribution from which the observed statistic can be assessed and an empirical p value is assigned. Singleton cases-controls are simply considered as founders with no descendants. For multi-site analyses, simulations are generated in a site-specific manner and overall association evidence is based on a CochranMantel-Haenszel meta-statistic across sites (Mantel and Haenszel 1959; Agresti 1990; Curtin et al. 2007 ). The primary analysis was the allele test for association for each of the 25 SNPs (asymptotically equivalent to a trend test). Up to 10 million simulations were used in the null distribution to estimate p values, depending on the necessary resolution required. Analysis began with 10,000 simulations and for SNPs with an empirical p value ≤0.1, an additional 10× number of simulations were performed; this process was repeated until a maximum of 10 million simulations were performed. A significance threshold of p ≤ 1E −3 was used to declare statistical significance accounting for multiple tests, which represents a Bonferroni corrected p value for 25 tests and 2 phenotypes (corrected alpha = 0.05/50). A Q test was used to identify SNPs that exhibited significant heterogeneity across sites. As follow-up, secondary to the main effects analyses described above, three additional analyses were performed using Genie. First, we tested all two-way interactions between all pairs of SNPs (assessed by significance of the interaction coefficient in a logistic regression framework). Second, we compared aggressive cases to non-aggressive cases by recoding aggressive cases as 'cases' and non-aggressive cases as 'controls' and performed tests of association at each marker. Third, we estimated a genetic risk score based on the number of risk alleles carried across the SNPs identified as significant in the main analyses. To avoid sparse data for the number of risk alleles, the extremes of the scale were collapsed to contain the top/bottom 5 % of the data, the resulting categories were: 0-8, 9, 10, …, 16, 17, 18-32 risk alleles carried. Only individuals with genotype data at all markers were included in the analysis. A trend test across these groups, weighted by the number of risk alleles, was used to compare the distributions for cases and controls. The genetic risk score test was repeated using the nonfamilial cases supplied by several of the contributing sites in order to establish the extent to which the genetic risk may differ between familial and non-familial prostate cancer cases. Table 3 shows the results of the primary analyses: metaanalysis combining data from all sites for the phenotypes consisting of all prostate cancer cases and for aggressive cases only. For the prostate cancer phenotype, 20 of the 25 SNPs were nominally significant (p ≤ 0.05), and 16 remained statistically significant after correction for multiple testing (p values ranging from 1E −3 to ≤1E10 −7 ). Replicated SNPs were on chromosomal bands 6q25, 7p15, 8q24, 10q11, 11q13, 17q12, 17q24, and Xp11. The odds ratios for all but 1 of the significant SNPs were less extreme than the originally published findings, as is often the situation in replication studies, although perhaps surprising for familial cases (Table 3) .
Results
For the aggressive prostate cancer phenotype, 16 markers showed at least nominal evidence and 8 of the 25 SNPs were statistically significant after correcting for multiple testing (p values ranging from 1.3E −3 to ≤1E10 −7 ). Qualitatively, the results for the aggressive phenotype were similar to the results of all prostate cancer cases indicating that these SNPs do not offer substantial discrimination between these two clinically distinguishable phenotypes. For any SNPs that were significant for both phenotypes, the odds ratio was consistently more extreme for aggressive prostate cancer; although none were significantly different. In accordance with this, in the secondary analysis of aggressive versus non-aggressive disease, no statistically significant differences were found (results not shown).
The results for the 14 study sites are reported in Supplemental Fig. 1 for all prostate cancer and in Supplemental Fig. 2 for aggressive prostate cancer, depicted in Forrest plots. Four SNPs indicated significant heterogeneity across sites (Q test p ≤ 1E −3 ); two at 8q24 (rs1447295; rs10090154), 9q33 (rs1571801), and Xp11 (rs5945619). Three of these 4 SNPs were significantly replicated, and by inspection of the Forrest plots, it can be seen that the by-site odds ratio estimates vary with one or two sites having extreme risk estimates but in the same direction as the meta-analysis result. The fourth SNP, at rs1571801 on 9q33, was not significant in the meta-analysis. It is notable that for this SNP the AAHPC site had a by-site significant OR estimate [OR = 1.7; 95 % CI = (1.2, 2.5)] which was in the opposite direction from most of the other sites. The odds ratio estimate for the aggressive phenotype for this site at this marker was even more extreme [OR = 2.4; 95 % CI = (1.5, 4.4)]. The AAHPC site differs from the other sites in that it is composed of African American families, indicating that this SNP may have a role in familial prostate cancer for this ethnic group even though the marker failed to achieve significance overall. The SNP rs1571801 is an intronic polymorphism in the DAB2IP gene, a documented tumor suppressor that has been observed to be aberrantly methylated in some prostate and lung cancers (Yano et al. 2005) and has been associated with early onset prostate cancer in a set of 754 Caucasians (Lange et al. 2012 ). According to 1,000 Genomes project, the minor allele frequency of this SNP does exhibit some variation between ethnic groups (5 % in Asians; 15 % in Africans; 20 % in admixed Americans; 24 % in Europeans), indicating that this SNP may be in linkage disequilibrium with some causal variant(s) in the African American prostate cancer families in this study, but not in the familial cases studied with other ancestral backgrounds. The analysis of all two-way interactions failed to identify any statistically significant interactions, after adjusting for multiple testing.
The results of the genetic risk analysis appear in Table 4 . The table shows the ORs and 95 % CIs of familial cases and controls comparing the number of risk alleles carried across the 16 replicated SNPs. In a test for trend weighted by the number of risk alleles, familial prostate cancer cases were significantly different than controls (p ≤ 1E −6 ). The results presented in Table 4 show that several adjacent categories of risk alleles carried exhibit similar levels of risk and could be collapsed. For instance, using a baseline ≤8 risk alleles (lowest 10 % of distribution), the increased risk for familial cases was approximately 1.6 for 9 or 10 risk alleles (19 % of the population), 1.93 for 11-13 risk alleles (40 %), and 2.84 for 14+ alleles (31 %). It is notable that when taken together, these 16 risk loci appear to be able to distinguish extreme groups that could be clinical valuable for determining early or more frequent screening for prostate cancer prevention. This analysis was repeated for population cases (results appear in Supplemental Table 1) and also found to be highly significant (p ≤ 1E −6 ). The increased risks were estimated to be approximately 1.40 for 9 or 10 risk alleles, 1.70 for 11-13 risk alleles, and 2.74 for 14+ alleles. The difference between familial and population cases was statistically significant (p ≤ 1E −6 ), with familial cases carrying more risk alleles, further confirming that family history is an important determinant in prostate risk.
Discussion
This familial case-control analysis of 9,560 familial prostate cancer cases significantly confirmed 16 of 25 SNPs (p ≤ 1E −3 ) previously reported to be associated with prostate cancer in population-based GWAS. This is compared to only three SNPs that could be replicated at the same significance using a FBAT analysis nested in the same genotype data (Jin et al. 2012) . The clear advantage of this analysis strategy (using related familial cases in a traditional casecontrol design) is the ability to use all the available genotype data. This produced a notable enhancement to statistical power. With the increased sample size, there was sufficient power for a subset analysis for aggressive disease, for which association of an SNP in the 2p15 locus for these familial cases was validated. Specifically, beyond the three loci with significant evidence from the FBAT analysis (10q11, 17q24 and Xp11), significant replication evidence for SNPs at 5 additional loci was shown: 2q15 (aggressive disease only), 7p15, 8q24, 11q13, and 17q12.
The results of this analysis highlight the benefit of using the case-control design, even with family-based data. The approach reported here was enabled by the flexible empirical approach contained in the Genie software that can appropriately account for the relatedness among cases. Furthermore, Genie software also provides a valid means to adjust for site-specific effects in a meta-analysis framework, and the ability to test for interaction effects and multi-locus analyses (such as a genetic risk score).
An analysis of familial aggressive cases versus familial non-aggressive prostate cancer cases was performed, but did not identify any statistically significant differences. This outcome indicates that, at least for the definition of aggressiveness that we used, these 25 SNPs do not distinguish between risk for aggressive and non-aggressive prostate cancer. The fact that two regions failed to achieve significance in the aggressive phenotype analysis but did achieve significance in the all PRCA phenotype analysis (6q25 and 7p15) indicates that this outcome is more likely an artifact of diminishing sample size and not due to a clinically important mechanism between the two disease definitions (the two analyses provided very similar odds ratios).
The genetic risk score based on the 16 replicated SNPs was an attempt to consider the multi-locus combined risk across multiple disease-associated SNPs. This analysis revealed that, although the individual SNP ORs were less extreme than the initial reports, that consider all 16 loci together, the familial prostate cancer cases carry significantly more risk alleles than do sporadic cases, indicating that they are enriched for these genetic associations. This outcome indicates that these families may be of great value for sequencing efforts to identify the genetic factors underlying these associations. Indeed, the ICPCG has already made a strong effort towards that objective. This observation of stronger genetic risk in familial disease is consistent with a recent report that positive family history doubles lifetime risk of prostate cancer above that attributable to carrying all risk alleles across 26 common variants (Macinnis et al. 2011) . Another recent report of a genetic risk score analysis comparing population ascertained cases and controls compared genotypes collected on 33 common variants previously shown to be associated with prostate cancer and demonstrated only a marginal improvement in prostate cancer prediction over prostate specific antigen screening alone (Johansson et al. 2012) . This question remains to be answered for familial prostate cancer where the effects appear to be larger.
In conclusion, these observations support that the majority of SNPs identified from GWAS using population-based case-control cohorts likely also play a role in the risk of familial disease.
